Key Drivers
- Liquidity rebound
- No revenue
- Ongoing burn
AIAI Summary
CMPS is now a regulatory-execution story with real upside from FDA rolling review and the priority voucher, but with no revenue yet and ongoing cash burn/dilution, it remains a high-risk, milestone-driven bet that only works if approval quickly converts into early commercialization.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity rebound
- •No revenue
- •Ongoing burn
CMPS's balance sheet and near-term liquidity improved sharply in Q1 2026, but the gains were driven by financing rather than operations, with no revenue, ongoing cash burn, and dilution risk still limiting fundamental quality.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Support holding
- •Momentum cooling
CMPS remains technically constructive after a sharp rebound from $11.03 to $15.07, but the recent pullback to $13.62 shows momentum has cooled and the $12.50-$12.65 support must hold before a move through the mid-$14s can resume.
Sharp recovery from $11.03 to $15.07, then a pullback to $13.62 signaled a brief momentum stall
Sentiment & News
Key News Insights:
- •Inducement grants
- •Phase 3 progress
- •Q4 data watch
Compass Pathways announced routine inducement grants for eight new hires while broader mental-health biotech news showed a depression-drug Phase 3 program advancing to 86% enrollment, signaling continued clinical and operational momentum. ക
The news is modestly positive for CMPS sentiment, as it reinforces ongoing execution and keeps the market focused on upcoming late-stage clinical data
Similar Companies in Healthcare
Other companies in the same sector with AI ratings